CytoDyn (STU:296) 12-1 Month Momentum %: -23.28% (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:296 CytoDyn Inc STU:296
31 GF Score
Price €0.17
! 1 Warning Sign
View Full Analysis

What is CytoDyn 12-1 Month Momentum %?

CytoDyn STU:296 +0.58% 31 12-1 Month Momentum % is -23.28% as of Sep. 21, 2026. GuruFocus rates STU:296 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,350 Biotechnology companies, CytoDyn ranks worse than 59.7% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-21), CytoDyn's 12-1 Month Momentum % is -23.28%.

The industry rank for CytoDyn's 12-1 Month Momentum % or its related term are showing as below:

STU:296's 12-1 Month Momentum % is ranked worse than
59.7% of 1350 companies
in the Biotechnology industry
Industry Median: -20.6 vs STU:296: -23.28

CytoDyn  (STU:296) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

CytoDyn 12-1 Month Momentum % Related Terms

STU:296 vs OBIO, IRD, VNDA: 12-1 Month Momentum % Comparison

For the Biotechnology subindustry, CytoDyn's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn 12-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where CytoDyn's 12-1 Month Momentum % falls into.


STU:296
31GF Score
CytoDyn Inc STU:296
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn  (STU:296) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of -23.28% mean?
CytoDyn (STU:296) has a 12-1 Month Momentum % of -23.28% as of Sep. 21, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on CytoDyn and its competitors. According to the industry distribution chart, CytoDyn ranks #806 out of 1350 companies in the Biotechnology industry, placing it in the top 59.7%.
Is CytoDyn's 12-1 Month Momentum % too high?
CytoDyn's current 12-1 Month Momentum % is -23.28%. Based on the distribution chart, CytoDyn ranks #806 out of 1350 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CytoDyn has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's 12-1 Month Momentum % compare to OBIO and IRD?
According to the Biotechnology industry distribution chart, CytoDyn ranks #806 out of 1350 companies for 12-1 Month Momentum %. This places CytoDyn in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on CytoDyn and its competitors. CytoDyn's current 12-1 Month Momentum % is -23.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current 12-1 Month Momentum % of -23.28%. The current 12-1 Month Momentum % is -23.28%. CytoDyn's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For CytoDyn (STU:296), the current 12-1 Month Momentum % is -23.28% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
31GF Score

Get the complete analysis for STU:296

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.17
Price